Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345794
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2024-03-28
Brief Title:
A Study to Assess LY4100511 DC-853 in Healthy Adult Participants
Sponsor:
DICE Therapeutics Inc a wholly owned subsidiary of Eli Lilly and Company
Organization:
DICE Therapeutics Inc a wholly owned subsidiary of Eli Lilly and Company
Study Overview
Official Title:
A Phase 1 Single-Center Open-Label 3-Cohort Fixed-Sequence Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 DC-853 When Orally Administered Alone When Coadministered With Itraconazole Fluconazole Or Carbamazepine In Healthy Adult Participants
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to assess the effect of multiple doses of itraconazole fluconazole and carbamazepine on single dose pharmacokinetic of LY4100511 DICE-853 in healthy participants The study will also evaluate the safety and tolerability of LY4100511 DICE-853 with itraconazole fluconazole and carbamazepine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J5C-MC-FOAG | OTHER | DICE Therapeutics a wholly owned subsidiary of Eli Lilly and Company | None |